In this study, it is proposed for the first time that NDC1 is related to tumor chemotherapy resistance, and then we need to analyze the specific drugs targeting NDC1 drug sensitivity to pancreatic cancer through in-depth study, in order to further guide clinical drug use. This evidence concerns the gene NDC1 and familial pancreatic carcinoma.